Annual General Meeting CEO Presentation

Thank you for your interest in our anticancer product tigilanol tiglate. We post details of our clinical trials on clinical trial registries, such as the Australian New Zealand Clinical Trials Registry (ANZCTR) at www.anzctr.org.au.

Please note:

• QBiotics is not involved in assessing patients or recommending eligibility for clinical trials – this is something only the independent trial clinicians can undertake.
• If you are interested in participating in one of our clinical trials please speak with your oncologist regarding the trial and its suitability to your specific problem.
• We are unable to discuss any aspects of these trials with potential patients and unfortunately, we cannot respond to emails or phone requests for information about these clinical trials.

We understand how truly difficult this time is for those affected by cancer, as cancer has touched the lives, either personally or through our loved ones, of many of us at QBiotics. Please be assured that we are one hundred percent committed to develop products as quickly as possible that effectively and safely address challenging conditions.

With warm regards, the QBiotics team.

Enquiries@qbiotics.com

Thank you for your interest in our veterinary programme.

Tigilanol tiglate, our lead oncology compound has now been commercialised as a veterinary oncology product, STELFONTA^®*.

STELFONTA* is approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Veterinary Medicines Directorate (VMD), Australian Pesticides and Veterinary Medicine (APVMA) and Swissmedic; making it the first pharmaceutical treatment available for non resectable, non-metastatic mast cell tumours. As STELFONTA is registered as a prescription product, your veterinarian will be able to decide the best treatment for your dog.

We appreciate how distressing a cancer diagnosis for your pet can be, and wish you and your dog the very best during this time.

Warmly, the QBiotics team.

Enquiries@qbiotics.com

---

* This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.

At QBiotics we are proud to be a small part of an important movement driving advances in oncology. Our recently registered pharmaceutical to treat canine mast cell tumours, STELFONTA^® (tigilanol tiglate), is backed by a rigorous clinical research programme that we are committed to continue, with the aim of improving the health of companion animals. We are excited to launch the QBiotics’ Research Grant, to support veterinary oncologists and those with a special interest in oncology to deepen our collective understanding of the potential to use STELFONTA to treat solid tumours.

Contact Dr Pamela Jones for details pamela.jones@qbiotics.com